CMMB News and Press, Chemomab Therapeutics Ltd. From 11/13/23

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 PR Newswire — ...

2023-11-09 10:39:17 ET More on Chemomab Therapeutics Chemomab Therapeutics receives Nasdaq notice regarding minimum bid price requirement Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial...

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire — Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 202...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Chemomab Therapeutics Ltd. (CMMB) is expected to report $-0.6 for Q3 2023

2023-11-06 16:46:34 ET More on Chemomab Therapeutics Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial information for Chemomab Therapeutics For further details see: Chemomab Therapeu...

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement PR Newswire -- Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market-- TEL AVIV, Israel , Nov. 6, 2023 /PRNewswire/ -- Chemomab Therapeu...

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company deve...

2023-10-16 16:47:19 ET More on Chemomab Therapeutics Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial information for Chemomab Therapeutics For further details see: Chemomab Therapeu...

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference PR Newswire -- CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in ...